Last update 21 Nov 2024
Anti-EGFR/IL-13R alpha 2 CAR-T cell therapy(Tmunity Therapeutics/University of Pennsylvania)
Last update 21 Nov 2024
Overview
Basic Info
Drug Type CAR-T |
Synonyms AntiEGFR/IL13R2 CAR T cell therapy, AntiEGFR/IL13Ra2 CAR T cell therapy, AntiEGFR/IL13Ralfa2 CAR T cell therapy |
Target |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), IL-13Rα2 inhibitors(Interleukin-13 receptor subunit alpha-2 inhibitors), Gene transference + [1] |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
2
Clinical Trials associated with Anti-EGFR/IL-13R alpha 2 CAR-T cell therapy(Tmunity Therapeutics/University of Pennsylvania)Phase 1, Open-label Study Evaluating the Safety and Feasibility of CART-EGFR-IL13Ra2 Cells in Patients With EGFR-Amplified Recurrent Glioblastoma
Phase 1 Study of EGFRvIII-Directed CAR T Cells Combined With PD-1 Inhibition in Patients With Newly Diagnosed, MGMT-Unmethylated Glioblastoma
100 Clinical Results associated with Anti-EGFR/IL-13R alpha 2 CAR-T cell therapy(Tmunity Therapeutics/University of Pennsylvania)
Login to view more data
100 Translational Medicine associated with Anti-EGFR/IL-13R alpha 2 CAR-T cell therapy(Tmunity Therapeutics/University of Pennsylvania)
Login to view more data
100 Patents (Medical) associated with Anti-EGFR/IL-13R alpha 2 CAR-T cell therapy(Tmunity Therapeutics/University of Pennsylvania)
Login to view more data
100 Deals associated with Anti-EGFR/IL-13R alpha 2 CAR-T cell therapy(Tmunity Therapeutics/University of Pennsylvania)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| EGFR mutation Glioblastoma | Phase 1 | US | 24 Feb 2023 | |
| EGFR mutation Glioblastoma | Phase 1 | US | 24 Feb 2023 | |
| Recurrent Glioblastoma | Phase 1 | US | 24 Feb 2023 | |
| Recurrent Glioblastoma | Phase 1 | US | 24 Feb 2023 | |
| Glioblastoma | Preclinical | US |  Tmunity Therapeutics, Inc.Startup | - |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free